Your browser doesn't support javascript.
loading
Targeted and immunotherapies in BRAF mutant melanoma: where we stand and what to expect.
Bai, X; Flaherty, K T.
Affiliation
  • Bai X; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital and Institute, Beijing, China.
  • Flaherty KT; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
Br J Dermatol ; 185(2): 253-262, 2021 08.
Article in En | MEDLINE | ID: mdl-32652567
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Proto-Oncogene Proteins B-raf / Melanoma Type of study: Clinical_trials Limits: Humans Language: En Journal: Br J Dermatol Year: 2021 Document type: Article Affiliation country: China
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Proto-Oncogene Proteins B-raf / Melanoma Type of study: Clinical_trials Limits: Humans Language: En Journal: Br J Dermatol Year: 2021 Document type: Article Affiliation country: China